Friday 6 November 2026
Export GKOS’s income statement to Excel — free account
Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
224.21
4.23
+1.92%
Follow GKOS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
12.73 | 11.33 | 13.41 | 14.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 269.42 | |
P/Operating CF |
943.64 | (498.69) | 554.57 | 251.61 | |
P/B ratio |
9.84 | 9.31 | 12.04 | 13.53 | |
Price to Tangible BV |
14.43 | 13.26 | 16.82 | 18.33 | |
EV/Sales |
12.86 | 11.46 | 13.51 | 14.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(441.27) | (718.34) | (8,716.70) | 203.61 | |
EV/FCF |
(167.07) | (180.03) | (678.98) | 269.68 | |
Quick Ratio |
3.82 | 4.43 | 4.15 | 3.84 | |
Current Ratio |
4.69 | 5.43 | 5.04 | 4.57 | |
Net Debt/EBITDA |
1.66 | 29.18 | 30.16 | (25.55) | |
Debt/Assets |
7.62% | 7.58% | 7.32% | 6.83% | |
Debt/Equity |
0.10 | 0.10 | 0.10 | 0.09 | |
Asset Turnover |
0.54 | 0.59 | 0.64 | 0.70 | |
Operating CF/Net income |
(0.05) | 0.63 | (0.81) | 19.11 | |
Capex/Depreciation |
(0.23) | (0.31) | (0.27) | (0.21) | |
Interest Coverage |
(122.05) | (17.65) | (11.83) | 0.76 | |
Research and Development Expense of Revenue |
30.50% | 29.32% | 28.45% | 22.79% | |
Selling, General and Administrative Expense of Revenue |
66.17% | 61.73% | 62.53% | 62.05% | |
Intangible Assets out of Total Assets |
0.23 | 0.22 | 0.21 | 0.19 | |
Share Based Compensation of Revenue |
12.09% | 12.71% | 15.55% | 8.42% | |
Graham Net Nets |
0.04 | 0.04 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.89%) | (3.05%) | (2.33%) | (1.79%) | |
Free Cash Flow Yield |
(0.60%) | (0.56%) | (0.15%) | 0.37% | |
Revenue per Share |
2.50 | 2.60 | 3.16 | 3.57 | |
Operating CF per Share |
0.12 | (0.22) | 0.25 | 0.65 | |
Capex per Share |
(0.05) | (0.07) | (0.05) | (0.04) | |
Free Cash Flow per Share |
0.07 | (0.28) | 0.21 | 0.62 | |
Cash per Share |
4.87 | 4.77 | 4.87 | 5.70 | |
Shareholders Equity per Share |
11.47 | 11.56 | 11.60 | 12.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.47 | 11.56 | 11.60 | 12.14 | |
Free Cash Flow |
3.93 | (16.48) | 12.09 | 36.49 | |
Working Capital |
373.71 | 396.34 | 413.45 | 452.92 | |
Capital Expenditures |
(2.91) | (3.96) | (2.74) | (2.08) | |
Net Current Asset Value |
237.65 | 263.36 | 277.74 | 317.40 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
84.68 | 95.61 | 110.94 | 124.34 | |
Average Payables |
18.83 | 17.49 | 16.41 | 22.15 | |
Average Inventory |
60.62 | 60.92 | 61.96 | 62.45 | |
Average Assets |
934.12 | 929.75 | 953.74 | 989.45 | |
Average Common Equity |
711.54 | 717.44 | 723.80 | 743.41 |
Columns are period end dates · fundamentals updated 5 Nov 2026